Agreements reached under this partnership
Business alliance- 1
Generation of high-value experimental data
- 2
Deeper understanding of structure–activity relationships in RNA recognition
- 3
Establishment of design criteria that may be used in future discovery research
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
As no upfront payments or other contractual payments will be exchanged in connection with the signing of the memorandum, there is no change to our earnings forecast for the fiscal year ending December 2026. We expect the results of the joint drug discovery research to contribute to an appropriate increase in our corporate value over the medium to long term as research and development and commercialisation progress.
| Item | Details |
|---|---|
| Name of alliance partner | Syntara Limited |
| Alliance partner's business activities | Drug development focused on building a pipeline of small-molecule drugs for diseases involving inflammation and fibrosis |
| Alliance partner's location | New South Wales, Australia |
| Type of alliance | Business alliance |
| Details of the alliance | Generation of high-value experimental data, Deeper understanding of structure–activity relationships in RNA recognition, Establishment of design criteria that may be used in future discovery research |
| Contract Date | 2 November 2026 |
| Impact on Business Performance | As no upfront payments or other contractual payments will be exchanged in connection with the signing of the memorandum, there is no change to our earnings forecast for the fiscal year ending December 2026. We expect the results of the joint drug discovery research to contribute to an appropriate increase in our corporate value over the medium to long term as research and development and commercialisation progress. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The aim is to create small-molecule drugs targeting mRNA by combining Syntara’s chemical synthesis technology and drug development capabilities with VIS’s AI-driven mRNA-targeted drug discovery platform and cell-based experimental technology. The explanation also states that Syntara became interested in the technology after learning about VIS’s research papers, and that momentum for the joint research grew through exchanges between the researchers.